Lenalidomide may delay onset of myeloma-related bone, organ damage

ROCHESTER Minn. -- The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. [...]
Source: Mayo Clinic Research News - Category: Research Source Type: news